Mirum’s LIVMARLI Hits Primary Endpoint in Phase 3 EXPAND Study for Rare Liver Diseases
Event summary
- Mirum Pharmaceuticals' Phase 3 EXPAND study of LIVMARLI (maralixibat) met its primary endpoint, showing statistically significant improvement in cholestatic pruritus for ultra-rare liver diseases.
- The study enrolled 52 patients, with maralixibat demonstrating a 1.81-point improvement in ItchRO(Obs) severity score vs. 0.83 for placebo (p=0.0004).
- Secondary endpoints also achieved statistical significance, including a 70.1% reduction in serum bile acids for maralixibat vs. 3.5% for placebo.
- Mirum plans to submit a supplemental New Drug Application (sNDA) in the U.S. in the first half of 2027 based on these results.
The big picture
Mirum’s positive Phase 3 results for LIVMARLI reinforce its leadership in rare liver disease therapeutics, addressing a critical unmet need in cholestatic pruritus. The study’s success could pave the way for expanded indications, strengthening Mirum’s pipeline and commercial footprint in the rare disease space. The strategic significance lies in Mirum’s ability to leverage these results to potentially dominate a niche market with limited treatment options.
What we're watching
- Regulatory Pathway
- Whether the sNDA submission in early 2027 will lead to an expanded approval for LIVMARLI in additional ultra-rare cholestatic liver diseases.
- Commercial Expansion
- The potential impact of these results on Mirum’s commercial strategy, particularly in broadening the patient population eligible for LIVMARLI.
- Competitive Dynamics
- How this success positions Mirum against other companies developing treatments for rare cholestatic liver diseases.